| Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML CD DiNardo, IS Tiong, A Quaglieri, S MacRaild, S Loghavi, FC Brown, ... Blood, The Journal of the American Society of Hematology 135 (11), 791-803, 2020 | 469 | 2020 |
| Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy CC Chua, AW Roberts, J Reynolds, CY Fong, SB Ting, JM Salmon, ... Journal of Clinical Oncology 38 (30), 3506-3517, 2020 | 134 | 2020 |
| Phase Ib study of the anti-TIM-3 antibody MBG453 in combination with decitabine in patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) U Borate, J Esteve, K Porkka, S Knapper, N Vey, S Scholl, ... Blood 134, 570, 2019 | 81 | 2019 |
| Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome S Loo, R Dillon, A Ivey, NS Anstee, J Othman, IS Tiong, N Potter, ... Blood, The Journal of the American Society of Hematology 140 (22), 2407-2411, 2022 | 39 | 2022 |
| Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia CC Chua, D Hammond, A Kent, IS Tiong, MY Konopleva, DA Pollyea, ... Blood Advances 6 (13), 3879-3883, 2022 | 31 | 2022 |
| Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia DM Moujalled, FC Brown, CC Chua, MA Dengler, G Pomilio, NS Anstee, ... Blood 141 (6), 634-644, 2023 | 28 | 2023 |
| Retrospective review on isolated distal deep vein thrombosis (IDDVT)—a benign entity or not? P Ho, HY Lim, CC Chua, M Sleeman, M Tacey, G Donnan, H Nandurkar Thrombosis research 142, 11-16, 2016 | 23 | 2016 |
| Clinicopathological aspects of therapy-related acute myeloid leukemia and myelodysplastic syndrome CC Chua, S Fleming, AH Wei Best Practice & Research Clinical Haematology 32 (1), 3-12, 2019 | 20 | 2019 |
| Molecular patterns of response and outcome in the chemotherapy and venetoclax in elderly AML trial (CAVEAT study) AH Wei, CC Chua, S Tiong, CY Fong, SB Ting, S Macraild, JM Salmon, ... Blood 132, 333, 2018 | 19 | 2018 |
| Catheter-directed thrombolysis for submassive pulmonary embolism MA Chiarello, AK Sista Seminars in Interventional Radiology 35 (02), 122-128, 2018 | 17 | 2018 |
| Retrospective evaluation of venous thromboembolism: are all transient provoking events the same? CC Chua, HY Lim, M Tacey, H Nandurkar, P Ho European journal of haematology 99 (1), 18-26, 2017 | 16 | 2017 |
| AML-190: anti-TIM-3 antibody MBG453 in combination with hypomethylating agents (HMAs) in patients with high-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia: a … A Brunner, U Borate, J Esteve, K Porkka, S Knapper, N Vey, S Scholl, ... Clinical Lymphoma Myeloma and Leukemia 20, S188-S189, 2020 | 15 | 2020 |
| Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myeloma CC Chua, HY Lim, KL Chai, J Ong, S Sim, C Wood, M Dickinson, ... Bone marrow transplantation 53 (9), 1116-1123, 2018 | 15 | 2018 |
| Acquired mutations in BAX confer resistance to BH3 mimetics in acute myeloid leukemia DM Moujalled, FC Brown, G Pomilio, NS Anstee, V Litalien, ER Thompson, ... Blood 136, 7-8, 2020 | 13 | 2020 |
| A physician targeted intervention improves prescribing in chronic heart failure in general medical units CC Chua, A Hutchinson, M Tacey, S Parikh, WK Lim, C Aboltins BMC health services research 18, 1-8, 2018 | 10 | 2018 |
| Venous thromboembolism management in Northeast Melbourne: how does it compare to international guidelines and data? HY Lim, CC Chua, M Tacey, M Sleeman, G Donnan, H Nandurkar, P Ho Internal medicine journal 47 (9), 1034-1042, 2017 | 10 | 2017 |
| Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells CE Teh, H Peng, MX Luo, T Tan, M Trussart, LJ Howson, CC Chua, ... Blood advances 7 (12), 2733-2745, 2023 | 9 | 2023 |
| ALLG AMLM26 Phase 1B/2 study investigating novel therapies to target early relapse and clonal evolution as pre-emptive therapy in AML (INTERCEPT): A multi-arm, precision-based … AH Wei, HJ Iland, J Reynolds, S Loo, CC Chua, D Westerman, IS Tiong, ... Blood 140 (Supplement 1), 3341-3343, 2022 | 8 | 2022 |
| Anti-leukemic activity of single agent venetoclax in newly diagnosed acute myeloid leukemia: A sub-set analysis of the CAVEAT study CC Chua, J Reynolds, JM Salmon, C Fong, SB Ting, S Tiong, S Fleming, ... Blood 134, 462, 2019 | 7 | 2019 |
| Treatment practice and outcomes in FLT3-mutant acute myeloid leukemia in the pre-midostaurin era: a real-world experience from Australian tertiary hospitals CC Chua, A Grigg, J Singh, MP Droogleever, L Zhang, A Lim, CY Fong, ... Leukemia & lymphoma 61 (4), 848-854, 2020 | 6 | 2020 |
